Tech Company Financing Transactions
Argentis Pharmaceuticals Funding Round
Argentis Pharmaceuticals, based in Collierville, secured investment capital from Innova Memphis.
Transaction Overview
Company Name
Announced On
4/22/2008
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Innova Memphis (Ken Woody)
Proceeds Purpose
"We are excited about Innova's investment," said Tom Davis, president and CEO, arGentis Pharmaceuticals. "The investment will be instrumental in arGentis continuing to execute its strategic plan and in creating value for our stakeholders by allocating additional resources to move our dry eye therapies into clinical trials later this year. We also will continue to develop the infrastructure to move ARG201 into a Phase III clinical program. We welcome Ken to our board and look forward to working with him to achieve these important milestones. We also believe this significant investment demonstrates Innova's commitment in further expanding the biomedical community in the Memphis area."
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1016 W. Poplar Ave. 106-238
Collierville, TN 38017
USA
Collierville, TN 38017
USA
Phone
Website
Email Address
Overview
arGentis Pharmaceuticals, LLC is a specialty pharmaceutical company located in Memphis, Tenn. The company seeks to in-license therapies for chronic diseases with demonstrated proof of concept for further development and commercialization.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Davis
Chief Marketing Officer
Ralph Henderson
Chief Medical Officer
Andrew Kang
Chief Scientific Officer
Arnold Postlethwaite
VP - Bus. Development
Edward Jensen
Browse more venture capital transactions:
Prev: 4/21/2008: MediaBank venture capital transaction
Next: 4/22/2008: Resolvyx Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs